Phase 2 Myeloma Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 0 to 75 years who are functioning well enough day-to-day, measured by a standard performance score (Karnofsky score of 70% or higher for those 16 and older, or Lansky score of 50% or higher for those under 16).
• People who have a suitable matched bone marrow donor who is a family member, or a partially matched family member (confirm with trial site for exact matching requirements).
• People diagnosed with certain blood cancers or bone marrow conditions, including various types of leukemia (such as AML, ALL, CML, and others), lymphoma, multiple myeloma, myelodysplastic syndrome (MDS), myelofibrosis, or bone marrow failure — where the disease meets specific stage or remission requirements as assessed by a doctor.
• People with acute leukemia whose disease is in remission, meaning less than 5% abnormal cells are detected in the bone marrow and standard disease-detection tests show no remaining cancer.
• People with chronic myelogenous leukemia (CML) in an early or intermediate phase who have already tried at least two different targeted therapies, cannot tolerate available targeted therapies, or have a specific drug-resistance mutation called T315I.
• People with certain lymphomas (such as Burkitt's, T-cell, follicular, mantle cell, or large cell) at specific stages of relapse or remission, as determined by a treating doctor.
• People with relapsed multiple myeloma whose cancer has responded to chemotherapy and for whom an autologous (self-donor) transplant is not suitable.
• People with myelofibrosis who are dependent on blood transfusions or whose estimated survival is under 5 years based on standard scoring tools.
• People with bone marrow failure conditions (excluding Fanconi anaemia).
• People with HIV whose virus is undetectable, provided an infectious disease specialist has reviewed their case and a management plan is in place before transplant.
• People whose liver, kidney, heart, and lung function all meet minimum levels required for safe transplantation, as assessed by standard medical tests.
• People who are sexually active and of reproductive potential who agree to use adequate contraception during the study treatment period.
• People (or a parent or guardian, for children) who are willing and able to give written informed consent.

Who may not be able to join:

• People who are pregnant or breastfeeding, as the medications used in this trial are known to be harmful to a developing baby.
• People who have an active infection that has not yet been treated.
• People whose cancer has spread to or is currently active in the central nervous system (brain or spinal cord).
• People with CML that has progressed to blast crisis (an advanced, rapidly worsening phase) — unless the disease has been brought into remission with a plan for ongoing targeted therapy after transplant.
• People with intermediate or high-grade non-Hodgkin's lymphoma, mantle cell lymphoma, or Hodgkin's disease that is continuing to worsen despite salvage (rescue) treatment.
• People who have undergone a full-intensity (myeloablative) bone marrow transplant within the past 3 months.
• People whose disease is showing clear signs of getting worse on imaging scans or biopsy results.

Important: Always verify eligibility with the trial site directly before applying.